arterial injection of cytotoxic agents this method has a flexibility which makes it suitable for many further applications; for example, during or after therapy, or as a pre-operative measure in cancer surgery.
I conclude with a brief account of the treatment of widely disseminated solid cancer by the continuous intravenous administration of alkylating agents. The delivery of cytotoxic drugs by a continuous intravenous method can markedly lower the dose levels at which toxicity occurs. This enhancement of effect occurs particularly when antimetabolic substances such as methotrexate are used. This has been explained (Sullivan 1962) as being due to the exposure of cells sequentially for an extended period of time, as they enter a sensitive phase. A single injection will only expose a small proportion of cells which happen to be in a sensitive state. These circumstances do not, however, apply when the alkylating agents are used. These chemically reactive substances are effective even when cells are momentarily exposed to them. The only valid reason, then, for the continuous delivery of alkylating agents intravenously lies in the assumption that the blood supply to a tumour is not homogeneous, and that some parts of the tumour are less well supplied than others. Thus an anti-tumour agent may not have good access to all parts of the tumour at any one time.
Delivery of the agent continuously should ensure better penetration to all parts of the tumour thereby rendering the drug more effective.
Employing this principle, we have treated widely disseminated malignant melanoma with the alkylating agent melphalan either alone or in combination with other substances. In spite of giving melphalan in dosage approaching hkmatological tolerance it is apparent that only occasional temporary benefit can be hoped for. Undoubtedly the reason for the lack of success of this method has been its inherent inability to get tumour drug concentrations anywhere near that achieved when use is made of the isolation perfusion technique.
The Hsematological Aspects of Regional and Total Body Chemotherapy (Hamatology Department, Westminster Hospital, London) by J G Humble CVO MRCP The routes, methods and techniques by which chemotherapeutic agents have been administered to patients are: (1) Arterial perfusions.
(2) Arterial injections by a single dose technique. (3) Arterial infusions, lasting for many days. (4) Continuous intravenous infusions, again lasting for many days.
The potential effects of the agents used on the bone marrow, and hence the blood counts ofthese patients, must be taken into consideration. The actual drugs used were:
(1) Alkylating agentsnitrogen mustard (mustine HCI), melphalan (phenylalanine mustard) and thiotepa (triethylene thiophosphoramide).
(2) Antimetabolitesmethotrexate.
(1) Alkylating agents: The group of drugs called alkylating agents are extremely active chemically in solution. They attack the bound phosphate groups of desoxyribosenucleic acid (DNA) and thus cause disorganization of this spiral structure. The alkylating agents therefore attack cells synthesizing DNA and hence cause granulocytopenia, thrombocytopenia, lymphopenia. Ultimately continued and sufficient dosage will cause bone marrow aplasia, temporary or permanent. When these drugs are injected into an artery leading to a tumour, part of the dose is 'fixed' by the tumour, the rest must circulate and can produce bonemarrow depression. Examination of the bone marrow before and after such an injection causing leucopenia will show a reduction of the myelocytes and other granulocytes and the nucleated red cells. The underground structure of the marrow, plasma cells, lymphocytes and reticulum cells becomes more obvious. Repeated marrow examination using standard conditions has been of great use in control of the cases receiving intra-carotid injections of thiotepa. Should these drugs be given in large doses by continuous intravenous infusion, aplasia will certainly ensue. In these cases we prefer to take and store the patient's own marrow previously, using the techniques elaborated and described by Pegg & Kemp (1960) . This stored marrow may be reinfused if aplasia should occur.
(2) Antimetabolites: The chief antimetabolite used has been methotrexate. This compound interferes with folic acid metabolism. Thus overdosage produces the effects of acute folic acid deprivation: sore tongue, sore mouth, gastric upset and diarrhoea. There follows leucopenia, thrombocytopenia and megaloblastic anxmia. Response to this compound varies quite unpredictably from patient to patient, possibly due to differing folic acid stores. Though the peripheral blood resembles aplastic anemia, the marrow shows a megaloblastic response. Recovery is usually rapid on folinic acid therapy.
In the treatment of aplastic anmmia due to chemotherapeutic agents isolation in cubicles is essential; antibiotics are given only if required and corticosteroids are not indicated. The risk of systemic 'thrush' is very great if antibiotics are given to patients with white cell counts of less than 1,000 per c.mm. Septicxemia is a common complication and repeated blood cultures are of great assistance. Under such a conservative regime recovery will quite frequently occur if 'nice judgment' can keep the moulds and bacteria at bay. Only by common study of such cases by clinician and hematologist together can these anti-tumour chemotherapeutic agents be employed to the best interests of the patient. The simplest method of obtaining the pressure required for arterial infusion is by gravity feed; a pressure of 170 mm Hg can easily be provided and this is quite adequate in the vast majority of cases. The only apparatus required is a drip stand capable of being raised to eleven or twelve feet and a correspondingly long giving set. However, this method has several disadvantages.
In the first place, it is not usually possible to obtain the necessary elevation for hypertensive patients who may require infusion pressures as high as 300 mm Hg. Secondly, when the conventional drip chamber and clamp are used it is difficult to reduce the volume of fluid infused to less than 1,500 ml per day without considerable risk of the drip stopping. In some circumstances, this volume is excessive, particularly in children and patients with cardiac failure or impaired renal function. Thirdly, since the hydrostatic pressure of a drip infusion system is constant the flow rate is dependent on the resistance offered at the catheter tip. Consequently, the rate of infusion tends to be very variable and complete cessation is not uncommon. This can be very troublesome, especially to the nursing staff. Finally, the necessary height of the infusion apparatus causes considerable inconvenience when the bottles are changed.
In this paper we propose briefly to describe four devices which have helped to overcome the difficulties.
The first device is extremely simple and consists of a drip chamber made from a Pasteur pipette into which the fluid drips from a 0-7 mm hypodermic needle. The chamber is attached to the lower end of the long drip set, and from its outlet a length of fine-bore, thick-walled rubber tubing leads to the arterial catheter. Screw clamps are placed both above and below the chamber; the upper clamp serves as a coarse adjustment and the lower clamp as a fine adjustment of flow rate. If the inflow resistance is constant it is a simple matter to maintain a continuous infusion at rates of 400-600 ml daily.
However, since the inflow resistance is subject to considerable fluctuation a second piece of apparatus was designed to monitor the drip rate and to give an alarm if the infusion should stop. The device is operated by a special drip chamber into which two platinum electrodes are fused. As each drop falls it momentarily shorts these electrodes which are wired to a battery-operated ratemeter. In addition to a meter indicating the drip rate, the apparatus is arranged to flash a small lamp synchronously with each drop; this feature is especially useful to the night staff. If the infusion stops an alarm is operated, but this circuit is subject to a time delay of two minutes, so that if the drip restarts spontaneously in this time the alarm is not operated.
T-hese devices have helped considerably in the management of arterial infusions, but the uncommon problem posed by the severely hypertensive patient remains. Obviously the answer is some form of pump. The requirements of such a device may be listed as follows: (1) The infusion rate must be slow and constant, irrespective of inflow resistance. (2) A pressure switch should be provided in the infusion line to cut off the pump motor in the event of a complete blockage. (3) Sterilization must be simple. (4) The pump must be silent in operation. (5) The apparatus must be mechanically sound and capable of
